The efficacy of T-DM1 as an adjuvant, neoadjuvant, first-line and second-line metastatic therapy for HER2-positive breast cancer has been evaluated in five randomised Phase 3 trials (Table 1). The gene discussed is ERBB2; the disease is breast cancer.